1 Market Overview

1.1 Product Overview and Scope of Adoptive Cellular Immunotherapy

1.2 Classification of Adoptive Cellular Immunotherapy by Type

1.2.1 Overview: Global Adoptive Cellular Immunotherapy Market Size by Type: 2017 Versus 2021 Versus 2028

1.2.2 Global Adoptive Cellular Immunotherapy Revenue Market Share by Type in 2021

1.2.3 TIL

1.2.4 LAK

1.2.5 CAR-T

1.2.6 TCR-T

1.2.7 CIK

1.2.8 NK

1.2.9 DC

1.2.10 Other

1.3 Global Adoptive Cellular Immunotherapy Market by Application

1.3.1 Overview: Global Adoptive Cellular Immunotherapy Market Size by Application: 2017 Versus 2021 Versus 2028

1.3.2 Hospital

1.3.3 Cancer Hospital

1.3.4 Centers for Disease Control and Prevention

1.3.5 Rehabilitation Center

1.3.6 Other

1.4 Global Adoptive Cellular Immunotherapy Market Size & Forecast

1.5 Global Adoptive Cellular Immunotherapy Market Size and Forecast by Region

1.5.1 Global Adoptive Cellular Immunotherapy Market Size by Region: 2017 VS 2021 VS 2028

1.5.2 Global Adoptive Cellular Immunotherapy Market Size by Region, (2017-2022)

1.5.3 North America Adoptive Cellular Immunotherapy Market Size and Prospect (2017-2028)

1.5.4 Europe Adoptive Cellular Immunotherapy Market Size and Prospect (2017-2028)

1.5.5 Asia-Pacific Adoptive Cellular Immunotherapy Market Size and Prospect (2017-2028)

1.5.6 South America Adoptive Cellular Immunotherapy Market Size and Prospect (2017-2028)

1.5.7 Middle East and Africa Adoptive Cellular Immunotherapy Market Size and Prospect (2017-2028)

1.6 Market Drivers, Restraints and Trends

1.6.1 Adoptive Cellular Immunotherapy Market Drivers

1.6.2 Adoptive Cellular Immunotherapy Market Restraints

1.6.3 Adoptive Cellular Immunotherapy Trends Analysis

2 Company Profiles

2.1 Amgen Inc

2.1.1 Amgen Inc Details

2.1.2 Amgen Inc Major Business

2.1.3 Amgen Inc Adoptive Cellular Immunotherapy Product and Solutions

2.1.4 Amgen Inc Adoptive Cellular Immunotherapy Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.1.5 Amgen Inc Recent Developments and Future Plans

2.2 Autolus Therapeutics Plc

2.2.1 Autolus Therapeutics Plc Details

2.2.2 Autolus Therapeutics Plc Major Business

2.2.3 Autolus Therapeutics Plc Adoptive Cellular Immunotherapy Product and Solutions

2.2.4 Autolus Therapeutics Plc Adoptive Cellular Immunotherapy Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.2.5 Autolus Therapeutics Plc Recent Developments and Future Plans

2.3 Beijing Immunochina Medical Science & Technology Co Ltd

2.3.1 Beijing Immunochina Medical Science & Technology Co Ltd Details

2.3.2 Beijing Immunochina Medical Science & Technology Co Ltd Major Business

2.3.3 Beijing Immunochina Medical Science & Technology Co Ltd Adoptive Cellular Immunotherapy Product and Solutions

2.3.4 Beijing Immunochina Medical Science & Technology Co Ltd Adoptive Cellular Immunotherapy Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.3.5 Beijing Immunochina Medical Science & Technology Co Ltd Recent Developments and Future Plans

2.4 Bellicum Pharmaceuticals Inc

2.4.1 Bellicum Pharmaceuticals Inc Details

2.4.2 Bellicum Pharmaceuticals Inc Major Business

2.4.3 Bellicum Pharmaceuticals Inc Adoptive Cellular Immunotherapy Product and Solutions

2.4.4 Bellicum Pharmaceuticals Inc Adoptive Cellular Immunotherapy Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.4.5 Bellicum Pharmaceuticals Inc Recent Developments and Future Plans

2.5 Bristol-Myers Squibb Co

2.5.1 Bristol-Myers Squibb Co Details

2.5.2 Bristol-Myers Squibb Co Major Business

2.5.3 Bristol-Myers Squibb Co Adoptive Cellular Immunotherapy Product and Solutions

2.5.4 Bristol-Myers Squibb Co Adoptive Cellular Immunotherapy Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.5.5 Bristol-Myers Squibb Co Recent Developments and Future Plans

2.6 bluebird bio Inc

2.6.1 bluebird bio Inc Details

2.6.2 bluebird bio Inc Major Business

2.6.3 bluebird bio Inc Adoptive Cellular Immunotherapy Product and Solutions

2.6.4 bluebird bio Inc Adoptive Cellular Immunotherapy Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.6.5 bluebird bio Inc Recent Developments and Future Plans

2.7 CARsgen Therapeutics Ltd

2.7.1 CARsgen Therapeutics Ltd Details

2.7.2 CARsgen Therapeutics Ltd Major Business

2.7.3 CARsgen Therapeutics Ltd Adoptive Cellular Immunotherapy Product and Solutions

2.7.4 CARsgen Therapeutics Ltd Adoptive Cellular Immunotherapy Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.7.5 CARsgen Therapeutics Ltd Recent Developments and Future Plans

2.8 Celgene Corp

2.8.1 Celgene Corp Details

2.8.2 Celgene Corp Major Business

2.8.3 Celgene Corp Adoptive Cellular Immunotherapy Product and Solutions

2.8.4 Celgene Corp Adoptive Cellular Immunotherapy Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.8.5 Celgene Corp Recent Developments and Future Plans

2.9 Cell Medica Ltd

2.9.1 Cell Medica Ltd Details

2.9.2 Cell Medica Ltd Major Business

2.9.3 Cell Medica Ltd Adoptive Cellular Immunotherapy Product and Solutions

2.9.4 Cell Medica Ltd Adoptive Cellular Immunotherapy Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.9.5 Cell Medica Ltd Recent Developments and Future Plans

2.10 Cellular Biomedicine Group Inc

2.10.1 Cellular Biomedicine Group Inc Details

2.10.2 Cellular Biomedicine Group Inc Major Business

2.10.3 Cellular Biomedicine Group Inc Adoptive Cellular Immunotherapy Product and Solutions

2.10.4 Cellular Biomedicine Group Inc Adoptive Cellular Immunotherapy Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.10.5 Cellular Biomedicine Group Inc Recent Developments and Future Plans

2.11 Celularity Inc

2.11.1 Celularity Inc Details

2.11.2 Celularity Inc Major Business

2.11.3 Celularity Inc Adoptive Cellular Immunotherapy Product and Solutions

2.11.4 Celularity Inc Adoptive Cellular Immunotherapy Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.11.5 Celularity Inc Recent Developments and Future Plans

2.12 Celyad SA

2.12.1 Celyad SA Details

2.12.2 Celyad SA Major Business

2.12.3 Celyad SA Adoptive Cellular Immunotherapy Product and Solutions

2.12.4 Celyad SA Adoptive Cellular Immunotherapy Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.12.5 Celyad SA Recent Developments and Future Plans

2.13 Daiichi Sankyo Co Ltd

2.13.1 Daiichi Sankyo Co Ltd Details

2.13.2 Daiichi Sankyo Co Ltd Major Business

2.13.3 Daiichi Sankyo Co Ltd Adoptive Cellular Immunotherapy Product and Solutions

2.13.4 Daiichi Sankyo Co Ltd Adoptive Cellular Immunotherapy Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.13.5 Daiichi Sankyo Co Ltd Recent Developments and Future Plans

2.14 Fosun Pharmaceutical AG

2.14.1 Fosun Pharmaceutical AG Details

2.14.2 Fosun Pharmaceutical AG Major Business

2.14.3 Fosun Pharmaceutical AG Adoptive Cellular Immunotherapy Product and Solutions

2.14.4 Fosun Pharmaceutical AG Adoptive Cellular Immunotherapy Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.14.5 Fosun Pharmaceutical AG Recent Developments and Future Plans

2.15 Gilead Sciences Inc

2.15.1 Gilead Sciences Inc Details

2.15.2 Gilead Sciences Inc Major Business

2.15.3 Gilead Sciences Inc Adoptive Cellular Immunotherapy Product and Solutions

2.15.4 Gilead Sciences Inc Adoptive Cellular Immunotherapy Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.15.5 Gilead Sciences Inc Recent Developments and Future Plans

2.16 Guangzhou Anjie Biomedical Technology Co Ltd

2.16.1 Guangzhou Anjie Biomedical Technology Co Ltd Details

2.16.2 Guangzhou Anjie Biomedical Technology Co Ltd Major Business

2.16.3 Guangzhou Anjie Biomedical Technology Co Ltd Adoptive Cellular Immunotherapy Product and Solutions

2.16.4 Guangzhou Anjie Biomedical Technology Co Ltd Adoptive Cellular Immunotherapy Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.16.5 Guangzhou Anjie Biomedical Technology Co Ltd Recent Developments and Future Plans

2.17 Hangzhou Converd Co Ltd

2.17.1 Hangzhou Converd Co Ltd Details

2.17.2 Hangzhou Converd Co Ltd Major Business

2.17.3 Hangzhou Converd Co Ltd Adoptive Cellular Immunotherapy Product and Solutions

2.17.4 Hangzhou Converd Co Ltd Adoptive Cellular Immunotherapy Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.17.5 Hangzhou Converd Co Ltd Recent Developments and Future Plans

2.18 Hebei Senlang Biotechnology Inc Ltd

2.18.1 Hebei Senlang Biotechnology Inc Ltd Details

2.18.2 Hebei Senlang Biotechnology Inc Ltd Major Business

2.18.3 Hebei Senlang Biotechnology Inc Ltd Adoptive Cellular Immunotherapy Product and Solutions

2.18.4 Hebei Senlang Biotechnology Inc Ltd Adoptive Cellular Immunotherapy Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.18.5 Hebei Senlang Biotechnology Inc Ltd Recent Developments and Future Plans

2.19 HRAIN Biotechnology Co Ltd

2.19.1 HRAIN Biotechnology Co Ltd Details

2.19.2 HRAIN Biotechnology Co Ltd Major Business

2.19.3 HRAIN Biotechnology Co Ltd Adoptive Cellular Immunotherapy Product and Solutions

2.19.4 HRAIN Biotechnology Co Ltd Adoptive Cellular Immunotherapy Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.19.5 HRAIN Biotechnology Co Ltd Recent Developments and Future Plans

2.20 Juno Therapeutics Inc

2.20.1 Juno Therapeutics Inc Details

2.20.2 Juno Therapeutics Inc Major Business

2.20.3 Juno Therapeutics Inc Adoptive Cellular Immunotherapy Product and Solutions

2.20.4 Juno Therapeutics Inc Adoptive Cellular Immunotherapy Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.20.5 Juno Therapeutics Inc Recent Developments and Future Plans

2.21 Kite Pharma Inc

2.21.1 Kite Pharma Inc Details

2.21.2 Kite Pharma Inc Major Business

2.21.3 Kite Pharma Inc Adoptive Cellular Immunotherapy Product and Solutions

2.21.4 Kite Pharma Inc Adoptive Cellular Immunotherapy Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.21.5 Kite Pharma Inc Recent Developments and Future Plans

2.22 Nanjing Legend Biotech Co Ltd

2.22.1 Nanjing Legend Biotech Co Ltd Details

2.22.2 Nanjing Legend Biotech Co Ltd Major Business

2.22.3 Nanjing Legend Biotech Co Ltd Adoptive Cellular Immunotherapy Product and Solutions

2.22.4 Nanjing Legend Biotech Co Ltd Adoptive Cellular Immunotherapy Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.22.5 Nanjing Legend Biotech Co Ltd Recent Developments and Future Plans

2.23 NantKwest Inc

2.23.1 NantKwest Inc Details

2.23.2 NantKwest Inc Major Business

2.23.3 NantKwest Inc Adoptive Cellular Immunotherapy Product and Solutions

2.23.4 NantKwest Inc Adoptive Cellular Immunotherapy Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.23.5 NantKwest Inc Recent Developments and Future Plans

2.24 Nkarta Inc

2.24.1 Nkarta Inc Details

2.24.2 Nkarta Inc Major Business

2.24.3 Nkarta Inc Adoptive Cellular Immunotherapy Product and Solutions

2.24.4 Nkarta Inc Adoptive Cellular Immunotherapy Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.24.5 Nkarta Inc Recent Developments and Future Plans

2.25 Novartis AG

2.25.1 Novartis AG Details

2.25.2 Novartis AG Major Business

2.25.3 Novartis AG Adoptive Cellular Immunotherapy Product and Solutions

2.25.4 Novartis AG Adoptive Cellular Immunotherapy Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.25.5 Novartis AG Recent Developments and Future Plans

2.26 Ono Pharmaceutical Co Ltd

2.26.1 Ono Pharmaceutical Co Ltd Details

2.26.2 Ono Pharmaceutical Co Ltd Major Business

2.26.3 Ono Pharmaceutical Co Ltd Adoptive Cellular Immunotherapy Product and Solutions

2.26.4 Ono Pharmaceutical Co Ltd Adoptive Cellular Immunotherapy Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.26.5 Ono Pharmaceutical Co Ltd Recent Developments and Future Plans

2.27 Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd

2.27.1 Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd Details

2.27.2 Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd Major Business

2.27.3 Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd Adoptive Cellular Immunotherapy Product and Solutions

2.27.4 Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd Adoptive Cellular Immunotherapy Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.27.5 Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd Recent Developments and Future Plans

2.28 Sorrento Therapeutics Inc

2.28.1 Sorrento Therapeutics Inc Details

2.28.2 Sorrento Therapeutics Inc Major Business

2.28.3 Sorrento Therapeutics Inc Adoptive Cellular Immunotherapy Product and Solutions

2.28.4 Sorrento Therapeutics Inc Adoptive Cellular Immunotherapy Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.28.5 Sorrento Therapeutics Inc Recent Developments and Future Plans

2.29 Takara Bio Inc

2.29.1 Takara Bio Inc Details

2.29.2 Takara Bio Inc Major Business

2.29.3 Takara Bio Inc Adoptive Cellular Immunotherapy Product and Solutions

2.29.4 Takara Bio Inc Adoptive Cellular Immunotherapy Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.29.5 Takara Bio Inc Recent Developments and Future Plans

3 Market Competition, by Players

3.1 Global Adoptive Cellular Immunotherapy Revenue and Share by Players (2019, 2020, 2021, and 2022)

3.2 Market Concentration Rate

3.2.1 Top 3 Adoptive Cellular Immunotherapy Players Market Share in 2021

3.2.2 Top 10 Adoptive Cellular Immunotherapy Players Market Share in 2021

3.2.3 Market Competition Trend

3.3 Adoptive Cellular Immunotherapy Players Head Office, Products and Services Provided

3.4 Adoptive Cellular Immunotherapy Mergers & Acquisitions

3.5 Adoptive Cellular Immunotherapy New Entrants and Expansion Plans

4 Market Size Segment by Type

4.1 Global Adoptive Cellular Immunotherapy Revenue and Market Share by Type (2017-2022)

4.2 Global Adoptive Cellular Immunotherapy Market Forecast by Type (2023-2028)

5 Market Size Segment by Application

5.1 Global Adoptive Cellular Immunotherapy Revenue Market Share by Application (2017-2022)

5.2 Global Adoptive Cellular Immunotherapy Market Forecast by Application (2023-2028)

6 North America by Country, by Type, and by Application

6.1 North America Adoptive Cellular Immunotherapy Revenue by Type (2017-2028)

6.2 North America Adoptive Cellular Immunotherapy Revenue by Application (2017-2028)

6.3 North America Adoptive Cellular Immunotherapy Market Size by Country

6.3.1 North America Adoptive Cellular Immunotherapy Revenue by Country (2017-2028)

6.3.2 United States Adoptive Cellular Immunotherapy Market Size and Forecast (2017-2028)

6.3.3 Canada Adoptive Cellular Immunotherapy Market Size and Forecast (2017-2028)

6.3.4 Mexico Adoptive Cellular Immunotherapy Market Size and Forecast (2017-2028)

7 Europe by Country, by Type, and by Application

7.1 Europe Adoptive Cellular Immunotherapy Revenue by Type (2017-2028)

7.2 Europe Adoptive Cellular Immunotherapy Revenue by Application (2017-2028)

7.3 Europe Adoptive Cellular Immunotherapy Market Size by Country

7.3.1 Europe Adoptive Cellular Immunotherapy Revenue by Country (2017-2028)

7.3.2 Germany Adoptive Cellular Immunotherapy Market Size and Forecast (2017-2028)

7.3.3 France Adoptive Cellular Immunotherapy Market Size and Forecast (2017-2028)

7.3.4 United Kingdom Adoptive Cellular Immunotherapy Market Size and Forecast (2017-2028)

7.3.5 Russia Adoptive Cellular Immunotherapy Market Size and Forecast (2017-2028)

7.3.6 Italy Adoptive Cellular Immunotherapy Market Size and Forecast (2017-2028)

8 Asia-Pacific by Region, by Type, and by Application

8.1 Asia-Pacific Adoptive Cellular Immunotherapy Revenue by Type (2017-2028)

8.2 Asia-Pacific Adoptive Cellular Immunotherapy Revenue by Application (2017-2028)

8.3 Asia-Pacific Adoptive Cellular Immunotherapy Market Size by Region

8.3.1 Asia-Pacific Adoptive Cellular Immunotherapy Revenue by Region (2017-2028)

8.3.2 China Adoptive Cellular Immunotherapy Market Size and Forecast (2017-2028)

8.3.3 Japan Adoptive Cellular Immunotherapy Market Size and Forecast (2017-2028)

8.3.4 South Korea Adoptive Cellular Immunotherapy Market Size and Forecast (2017-2028)

8.3.5 India Adoptive Cellular Immunotherapy Market Size and Forecast (2017-2028)

8.3.6 Southeast Asia Adoptive Cellular Immunotherapy Market Size and Forecast (2017-2028)

8.3.7 Australia Adoptive Cellular Immunotherapy Market Size and Forecast (2017-2028)

9 South America by Country, by Type, and by Application

9.1 South America Adoptive Cellular Immunotherapy Revenue by Type (2017-2028)

9.2 South America Adoptive Cellular Immunotherapy Revenue by Application (2017-2028)

9.3 South America Adoptive Cellular Immunotherapy Market Size by Country

9.3.1 South America Adoptive Cellular Immunotherapy Revenue by Country (2017-2028)

9.3.2 Brazil Adoptive Cellular Immunotherapy Market Size and Forecast (2017-2028)

9.3.3 Argentina Adoptive Cellular Immunotherapy Market Size and Forecast (2017-2028)

10 Middle East & Africa by Country, by Type, and by Application

10.1 Middle East & Africa Adoptive Cellular Immunotherapy Revenue by Type (2017-2028)

10.2 Middle East & Africa Adoptive Cellular Immunotherapy Revenue by Application (2017-2028)

10.3 Middle East & Africa Adoptive Cellular Immunotherapy Market Size by Country

10.3.1 Middle East & Africa Adoptive Cellular Immunotherapy Revenue by Country (2017-2028)

10.3.2 Turkey Adoptive Cellular Immunotherapy Market Size and Forecast (2017-2028)

10.3.3 Saudi Arabia Adoptive Cellular Immunotherapy Market Size and Forecast (2017-2028)

10.3.4 UAE Adoptive Cellular Immunotherapy Market Size and Forecast (2017-2028)

11 Research Findings and Conclusion

12 Appendix

12.1 Methodology

12.2 Research Process and Data Source

12.3 Disclaimer

List of Tables

Table 1. Global Adoptive Cellular Immunotherapy Revenue by Type, (USD Million), 2017 VS 2021 VS 2028

Table 2. Global Adoptive Cellular Immunotherapy Revenue by Application, (USD Million), 2017 VS 2021 VS 2028

Table 3. Global Market Adoptive Cellular Immunotherapy Revenue (Million USD) Comparison by Region (2017 VS 2021 VS 2028)

Table 4. Global Adoptive Cellular Immunotherapy Revenue (USD Million) by Region (2017-2022)

Table 5. Global Adoptive Cellular Immunotherapy Revenue Market Share by Region (2023-2028)

Table 6. Amgen Inc Corporate Information, Head Office, and Major Competitors

Table 7. Amgen Inc Major Business

Table 8. Amgen Inc Adoptive Cellular Immunotherapy Product and Solutions

Table 9. Amgen Inc Adoptive Cellular Immunotherapy Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 10. Autolus Therapeutics Plc Corporate Information, Head Office, and Major Competitors

Table 11. Autolus Therapeutics Plc Major Business

Table 12. Autolus Therapeutics Plc Adoptive Cellular Immunotherapy Product and Solutions

Table 13. Autolus Therapeutics Plc Adoptive Cellular Immunotherapy Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 14. Beijing Immunochina Medical Science & Technology Co Ltd Corporate Information, Head Office, and Major Competitors

Table 15. Beijing Immunochina Medical Science & Technology Co Ltd Major Business

Table 16. Beijing Immunochina Medical Science & Technology Co Ltd Adoptive Cellular Immunotherapy Product and Solutions

Table 17. Beijing Immunochina Medical Science & Technology Co Ltd Adoptive Cellular Immunotherapy Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 18. Bellicum Pharmaceuticals Inc Corporate Information, Head Office, and Major Competitors

Table 19. Bellicum Pharmaceuticals Inc Major Business

Table 20. Bellicum Pharmaceuticals Inc Adoptive Cellular Immunotherapy Product and Solutions

Table 21. Bellicum Pharmaceuticals Inc Adoptive Cellular Immunotherapy Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 22. Bristol-Myers Squibb Co Corporate Information, Head Office, and Major Competitors

Table 23. Bristol-Myers Squibb Co Major Business

Table 24. Bristol-Myers Squibb Co Adoptive Cellular Immunotherapy Product and Solutions

Table 25. Bristol-Myers Squibb Co Adoptive Cellular Immunotherapy Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 26. bluebird bio Inc Corporate Information, Head Office, and Major Competitors

Table 27. bluebird bio Inc Major Business

Table 28. bluebird bio Inc Adoptive Cellular Immunotherapy Product and Solutions

Table 29. bluebird bio Inc Adoptive Cellular Immunotherapy Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 30. CARsgen Therapeutics Ltd Corporate Information, Head Office, and Major Competitors

Table 31. CARsgen Therapeutics Ltd Major Business

Table 32. CARsgen Therapeutics Ltd Adoptive Cellular Immunotherapy Product and Solutions

Table 33. CARsgen Therapeutics Ltd Adoptive Cellular Immunotherapy Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 34. Celgene Corp Corporate Information, Head Office, and Major Competitors

Table 35. Celgene Corp Major Business

Table 36. Celgene Corp Adoptive Cellular Immunotherapy Product and Solutions

Table 37. Celgene Corp Adoptive Cellular Immunotherapy Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 38. Cell Medica Ltd Corporate Information, Head Office, and Major Competitors

Table 39. Cell Medica Ltd Major Business

Table 40. Cell Medica Ltd Adoptive Cellular Immunotherapy Product and Solutions

Table 41. Cell Medica Ltd Adoptive Cellular Immunotherapy Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 42. Cellular Biomedicine Group Inc Corporate Information, Head Office, and Major Competitors

Table 43. Cellular Biomedicine Group Inc Major Business

Table 44. Cellular Biomedicine Group Inc Adoptive Cellular Immunotherapy Product and Solutions

Table 45. Cellular Biomedicine Group Inc Adoptive Cellular Immunotherapy Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 46. Celularity Inc Corporate Information, Head Office, and Major Competitors

Table 47. Celularity Inc Major Business

Table 48. Celularity Inc Adoptive Cellular Immunotherapy Product and Solutions

Table 49. Celularity Inc Adoptive Cellular Immunotherapy Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 50. Celyad SA Corporate Information, Head Office, and Major Competitors

Table 51. Celyad SA Major Business

Table 52. Celyad SA Adoptive Cellular Immunotherapy Product and Solutions

Table 53. Celyad SA Adoptive Cellular Immunotherapy Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 54. Daiichi Sankyo Co Ltd Corporate Information, Head Office, and Major Competitors

Table 55. Daiichi Sankyo Co Ltd Major Business

Table 56. Daiichi Sankyo Co Ltd Adoptive Cellular Immunotherapy Product and Solutions

Table 57. Daiichi Sankyo Co Ltd Adoptive Cellular Immunotherapy Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 58. Fosun Pharmaceutical AG Corporate Information, Head Office, and Major Competitors

Table 59. Fosun Pharmaceutical AG Major Business

Table 60. Fosun Pharmaceutical AG Adoptive Cellular Immunotherapy Product and Solutions

Table 61. Fosun Pharmaceutical AG Adoptive Cellular Immunotherapy Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 62. Gilead Sciences Inc Corporate Information, Head Office, and Major Competitors

Table 63. Gilead Sciences Inc Major Business

Table 64. Gilead Sciences Inc Adoptive Cellular Immunotherapy Product and Solutions

Table 65. Gilead Sciences Inc Adoptive Cellular Immunotherapy Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 66. Guangzhou Anjie Biomedical Technology Co Ltd Corporate Information, Head Office, and Major Competitors

Table 67. Guangzhou Anjie Biomedical Technology Co Ltd Major Business

Table 68. Guangzhou Anjie Biomedical Technology Co Ltd Adoptive Cellular Immunotherapy Product and Solutions

Table 69. Guangzhou Anjie Biomedical Technology Co Ltd Adoptive Cellular Immunotherapy Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 70. Hangzhou Converd Co Ltd Corporate Information, Head Office, and Major Competitors

Table 71. Hangzhou Converd Co Ltd Major Business

Table 72. Hangzhou Converd Co Ltd Adoptive Cellular Immunotherapy Product and Solutions

Table 73. Hangzhou Converd Co Ltd Adoptive Cellular Immunotherapy Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 74. Hebei Senlang Biotechnology Inc Ltd Corporate Information, Head Office, and Major Competitors

Table 75. Hebei Senlang Biotechnology Inc Ltd Major Business

Table 76. Hebei Senlang Biotechnology Inc Ltd Adoptive Cellular Immunotherapy Product and Solutions

Table 77. Hebei Senlang Biotechnology Inc Ltd Adoptive Cellular Immunotherapy Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 78. HRAIN Biotechnology Co Ltd Corporate Information, Head Office, and Major Competitors

Table 79. HRAIN Biotechnology Co Ltd Major Business

Table 80. HRAIN Biotechnology Co Ltd Adoptive Cellular Immunotherapy Product and Solutions

Table 81. HRAIN Biotechnology Co Ltd Adoptive Cellular Immunotherapy Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 82. Juno Therapeutics Inc Corporate Information, Head Office, and Major Competitors

Table 83. Juno Therapeutics Inc Major Business

Table 84. Juno Therapeutics Inc Adoptive Cellular Immunotherapy Product and Solutions

Table 85. Juno Therapeutics Inc Adoptive Cellular Immunotherapy Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 86. Kite Pharma Inc Corporate Information, Head Office, and Major Competitors

Table 87. Kite Pharma Inc Major Business

Table 88. Kite Pharma Inc Adoptive Cellular Immunotherapy Product and Solutions

Table 89. Kite Pharma Inc Adoptive Cellular Immunotherapy Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 90. Nanjing Legend Biotech Co Ltd Corporate Information, Head Office, and Major Competitors

Table 91. Nanjing Legend Biotech Co Ltd Major Business

Table 92. Nanjing Legend Biotech Co Ltd Adoptive Cellular Immunotherapy Product and Solutions

Table 93. Nanjing Legend Biotech Co Ltd Adoptive Cellular Immunotherapy Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 94. NantKwest Inc Corporate Information, Head Office, and Major Competitors

Table 95. NantKwest Inc Major Business

Table 96. NantKwest Inc Adoptive Cellular Immunotherapy Product and Solutions

Table 97. NantKwest Inc Adoptive Cellular Immunotherapy Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 98. Nkarta Inc Corporate Information, Head Office, and Major Competitors

Table 99. Nkarta Inc Major Business

Table 100. Nkarta Inc Adoptive Cellular Immunotherapy Product and Solutions

Table 101. Nkarta Inc Adoptive Cellular Immunotherapy Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 102. Novartis AG Corporate Information, Head Office, and Major Competitors

Table 103. Novartis AG Major Business

Table 104. Novartis AG Adoptive Cellular Immunotherapy Product and Solutions

Table 105. Novartis AG Adoptive Cellular Immunotherapy Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 106. Ono Pharmaceutical Co Ltd Corporate Information, Head Office, and Major Competitors

Table 107. Ono Pharmaceutical Co Ltd Major Business

Table 108. Ono Pharmaceutical Co Ltd Adoptive Cellular Immunotherapy Product and Solutions

Table 109. Ono Pharmaceutical Co Ltd Adoptive Cellular Immunotherapy Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 110. Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd Corporate Information, Head Office, and Major Competitors

Table 111. Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd Major Business

Table 112. Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd Adoptive Cellular Immunotherapy Product and Solutions

Table 113. Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd Adoptive Cellular Immunotherapy Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 114. Sorrento Therapeutics Inc Corporate Information, Head Office, and Major Competitors

Table 115. Sorrento Therapeutics Inc Major Business

Table 116. Sorrento Therapeutics Inc Adoptive Cellular Immunotherapy Product and Solutions

Table 117. Sorrento Therapeutics Inc Adoptive Cellular Immunotherapy Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 118. Takara Bio Inc Corporate Information, Head Office, and Major Competitors

Table 119. Takara Bio Inc Major Business

Table 120. Takara Bio Inc Adoptive Cellular Immunotherapy Product and Solutions

Table 121. Takara Bio Inc Adoptive Cellular Immunotherapy Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 122. Global Adoptive Cellular Immunotherapy Revenue (USD Million) by Players (2019, 2020, 2021, and 2022)

Table 123. Global Adoptive Cellular Immunotherapy Revenue Share by Players (2019, 2020, 2021, and 2022)

Table 124. Breakdown of Adoptive Cellular Immunotherapy by Company Type (Tier 1, Tier 2 and Tier 3)

Table 125. Adoptive Cellular Immunotherapy Players Head Office, Products and Services Provided

Table 126. Adoptive Cellular Immunotherapy Mergers & Acquisitions in the Past Five Years

Table 127. Adoptive Cellular Immunotherapy New Entrants and Expansion Plans

Table 128. Global Adoptive Cellular Immunotherapy Revenue (USD Million) by Type (2017-2022)

Table 129. Global Adoptive Cellular Immunotherapy Revenue Share by Type (2017-2022)

Table 130. Global Adoptive Cellular Immunotherapy Revenue Forecast by Type (2023-2028)

Table 131. Global Adoptive Cellular Immunotherapy Revenue by Application (2017-2022)

Table 132. Global Adoptive Cellular Immunotherapy Revenue Forecast by Application (2023-2028)

Table 133. North America Adoptive Cellular Immunotherapy Revenue by Type (2017-2022) & (USD Million)

Table 134. North America Adoptive Cellular Immunotherapy Revenue by Type (2023-2028) & (USD Million)

Table 135. North America Adoptive Cellular Immunotherapy Revenue by Application (2017-2022) & (USD Million)

Table 136. North America Adoptive Cellular Immunotherapy Revenue by Application (2023-2028) & (USD Million)

Table 137. North America Adoptive Cellular Immunotherapy Revenue by Country (2017-2022) & (USD Million)

Table 138. North America Adoptive Cellular Immunotherapy Revenue by Country (2023-2028) & (USD Million)

Table 139. Europe Adoptive Cellular Immunotherapy Revenue by Type (2017-2022) & (USD Million)

Table 140. Europe Adoptive Cellular Immunotherapy Revenue by Type (2023-2028) & (USD Million)

Table 141. Europe Adoptive Cellular Immunotherapy Revenue by Application (2017-2022) & (USD Million)

Table 142. Europe Adoptive Cellular Immunotherapy Revenue by Application (2023-2028) & (USD Million)

Table 143. Europe Adoptive Cellular Immunotherapy Revenue by Country (2017-2022) & (USD Million)

Table 144. Europe Adoptive Cellular Immunotherapy Revenue by Country (2023-2028) & (USD Million)

Table 145. Asia-Pacific Adoptive Cellular Immunotherapy Revenue by Type (2017-2022) & (USD Million)

Table 146. Asia-Pacific Adoptive Cellular Immunotherapy Revenue by Type (2023-2028) & (USD Million)

Table 147. Asia-Pacific Adoptive Cellular Immunotherapy Revenue by Application (2017-2022) & (USD Million)

Table 148. Asia-Pacific Adoptive Cellular Immunotherapy Revenue by Application (2023-2028) & (USD Million)

Table 149. Asia-Pacific Adoptive Cellular Immunotherapy Revenue by Region (2017-2022) & (USD Million)

Table 150. Asia-Pacific Adoptive Cellular Immunotherapy Revenue by Region (2023-2028) & (USD Million)

Table 151. South America Adoptive Cellular Immunotherapy Revenue by Type (2017-2022) & (USD Million)

Table 152. South America Adoptive Cellular Immunotherapy Revenue by Type (2023-2028) & (USD Million)

Table 153. South America Adoptive Cellular Immunotherapy Revenue by Application (2017-2022) & (USD Million)

Table 154. South America Adoptive Cellular Immunotherapy Revenue by Application (2023-2028) & (USD Million)

Table 155. South America Adoptive Cellular Immunotherapy Revenue by Country (2017-2022) & (USD Million)

Table 156. South America Adoptive Cellular Immunotherapy Revenue by Country (2023-2028) & (USD Million)

Table 157. Middle East & Africa Adoptive Cellular Immunotherapy Revenue by Type (2017-2022) & (USD Million)

Table 158. Middle East & Africa Adoptive Cellular Immunotherapy Revenue by Type (2023-2028) & (USD Million)

Table 159. Middle East & Africa Adoptive Cellular Immunotherapy Revenue by Application (2017-2022) & (USD Million)

Table 160. Middle East & Africa Adoptive Cellular Immunotherapy Revenue by Application (2023-2028) & (USD Million)

Table 161. Middle East & Africa Adoptive Cellular Immunotherapy Revenue by Country (2017-2022) & (USD Million)

Table 162. Middle East & Africa Adoptive Cellular Immunotherapy Revenue by Country (2023-2028) & (USD Million)

List of Figures

Figure 1. Adoptive Cellular Immunotherapy Picture

Figure 2. Global Adoptive Cellular Immunotherapy Revenue Market Share by Type in 2021

Figure 3. TIL

Figure 4. LAK

Figure 5. CAR-T

Figure 6. TCR-T

Figure 7. CIK

Figure 8. NK

Figure 9. DC

Figure 10. Other

Figure 11. Adoptive Cellular Immunotherapy Revenue Market Share by Application in 2021

Figure 12. Hospital Picture

Figure 13. Cancer Hospital Picture

Figure 14. Centers for Disease Control and Prevention Picture

Figure 15. Rehabilitation Center Picture

Figure 16. Other Picture

Figure 17. Global Adoptive Cellular Immunotherapy Market Size, (USD Million): 2017 VS 2021 VS 2028

Figure 18. Global Adoptive Cellular Immunotherapy Revenue and Forecast (2017-2028) & (USD Million)

Figure 19. Global Adoptive Cellular Immunotherapy Revenue Market Share by Region (2017-2028)

Figure 20. Global Adoptive Cellular Immunotherapy Revenue Market Share by Region in 2021

Figure 21. North America Adoptive Cellular Immunotherapy Revenue (USD Million) and Growth Rate (2017-2028)

Figure 22. Europe Adoptive Cellular Immunotherapy Revenue (USD Million) and Growth Rate (2017-2028)

Figure 23. Asia-Pacific Adoptive Cellular Immunotherapy Revenue (USD Million) and Growth Rate (2017-2028)

Figure 24. South America Adoptive Cellular Immunotherapy Revenue (USD Million) and Growth Rate (2017-2028)

Figure 25. Middle East and Africa Adoptive Cellular Immunotherapy Revenue (USD Million) and Growth Rate (2017-2028)

Figure 26. Adoptive Cellular Immunotherapy Market Drivers

Figure 27. Adoptive Cellular Immunotherapy Market Restraints

Figure 28. Adoptive Cellular Immunotherapy Market Trends

Figure 29. Amgen Inc Recent Developments and Future Plans

Figure 30. Autolus Therapeutics Plc Recent Developments and Future Plans

Figure 31. Beijing Immunochina Medical Science & Technology Co Ltd Recent Developments and Future Plans

Figure 32. Bellicum Pharmaceuticals Inc Recent Developments and Future Plans

Figure 33. Bristol-Myers Squibb Co Recent Developments and Future Plans

Figure 34. bluebird bio Inc Recent Developments and Future Plans

Figure 35. CARsgen Therapeutics Ltd Recent Developments and Future Plans

Figure 36. Celgene Corp Recent Developments and Future Plans

Figure 37. Cell Medica Ltd Recent Developments and Future Plans

Figure 38. Cellular Biomedicine Group Inc Recent Developments and Future Plans

Figure 39. Celularity Inc Recent Developments and Future Plans

Figure 40. Celyad SA Recent Developments and Future Plans

Figure 41. Daiichi Sankyo Co Ltd Recent Developments and Future Plans

Figure 42. Fosun Pharmaceutical AG Recent Developments and Future Plans

Figure 43. Gilead Sciences Inc Recent Developments and Future Plans

Figure 44. Guangzhou Anjie Biomedical Technology Co Ltd Recent Developments and Future Plans

Figure 45. Hangzhou Converd Co Ltd Recent Developments and Future Plans

Figure 46. Hebei Senlang Biotechnology Inc Ltd Recent Developments and Future Plans

Figure 47. HRAIN Biotechnology Co Ltd Recent Developments and Future Plans

Figure 48. Juno Therapeutics Inc Recent Developments and Future Plans

Figure 49. Kite Pharma Inc Recent Developments and Future Plans

Figure 50. Nanjing Legend Biotech Co Ltd Recent Developments and Future Plans

Figure 51. NantKwest Inc Recent Developments and Future Plans

Figure 52. Nkarta Inc Recent Developments and Future Plans

Figure 53. Novartis AG Recent Developments and Future Plans

Figure 54. Ono Pharmaceutical Co Ltd Recent Developments and Future Plans

Figure 55. Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd Recent Developments and Future Plans

Figure 56. Sorrento Therapeutics Inc Recent Developments and Future Plans

Figure 57. Takara Bio Inc Recent Developments and Future Plans

Figure 58. Global Adoptive Cellular Immunotherapy Revenue Share by Players in 2021

Figure 59. Adoptive Cellular Immunotherapy Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2021

Figure 60. Global Top 3 Players Adoptive Cellular Immunotherapy Revenue Market Share in 2021

Figure 61. Global Top 10 Players Adoptive Cellular Immunotherapy Revenue Market Share in 2021

Figure 62. Key Players Market Share Trend (Top 3 Market Share: 2020 VS 2021 VS 2022)

Figure 63. Global Adoptive Cellular Immunotherapy Revenue Share by Type in 2021

Figure 64. Global Adoptive Cellular Immunotherapy Market Share Forecast by Type (2023-2028)

Figure 65. Global Adoptive Cellular Immunotherapy Revenue Share by Application in 2021

Figure 66. Global Adoptive Cellular Immunotherapy Market Share Forecast by Application (2023-2028)

Figure 67. North America Adoptive Cellular Immunotherapy Sales Market Share by Type (2017-2028)

Figure 68. North America Adoptive Cellular Immunotherapy Sales Market Share by Application (2017-2028)

Figure 69. North America Adoptive Cellular Immunotherapy Revenue Market Share by Country (2017-2028)

Figure 70. United States Adoptive Cellular Immunotherapy Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 71. Canada Adoptive Cellular Immunotherapy Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 72. Mexico Adoptive Cellular Immunotherapy Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 73. Europe Adoptive Cellular Immunotherapy Sales Market Share by Type (2017-2028)

Figure 74. Europe Adoptive Cellular Immunotherapy Sales Market Share by Application (2017-2028)

Figure 75. Europe Adoptive Cellular Immunotherapy Revenue Market Share by Country (2017-2028)

Figure 76. Germany Adoptive Cellular Immunotherapy Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 77. France Adoptive Cellular Immunotherapy Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 78. United Kingdom Adoptive Cellular Immunotherapy Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 79. Russia Adoptive Cellular Immunotherapy Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 80. Italy Adoptive Cellular Immunotherapy Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 81. Asia-Pacific Adoptive Cellular Immunotherapy Sales Market Share by Type (2017-2028)

Figure 82. Asia-Pacific Adoptive Cellular Immunotherapy Sales Market Share by Application (2017-2028)

Figure 83. Asia-Pacific Adoptive Cellular Immunotherapy Revenue Market Share by Region (2017-2028)

Figure 84. China Adoptive Cellular Immunotherapy Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 85. Japan Adoptive Cellular Immunotherapy Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 86. South Korea Adoptive Cellular Immunotherapy Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 87. India Adoptive Cellular Immunotherapy Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 88. Southeast Asia Adoptive Cellular Immunotherapy Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 89. Australia Adoptive Cellular Immunotherapy Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 90. South America Adoptive Cellular Immunotherapy Sales Market Share by Type (2017-2028)

Figure 91. South America Adoptive Cellular Immunotherapy Sales Market Share by Application (2017-2028)

Figure 92. South America Adoptive Cellular Immunotherapy Revenue Market Share by Country (2017-2028)

Figure 93. Brazil Adoptive Cellular Immunotherapy Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 94. Argentina Adoptive Cellular Immunotherapy Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 95. Middle East and Africa Adoptive Cellular Immunotherapy Sales Market Share by Type (2017-2028)

Figure 96. Middle East and Africa Adoptive Cellular Immunotherapy Sales Market Share by Application (2017-2028)

Figure 97. Middle East and Africa Adoptive Cellular Immunotherapy Revenue Market Share by Country (2017-2028)

Figure 98. Turkey Adoptive Cellular Immunotherapy Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 99. Saudi Arabia Adoptive Cellular Immunotherapy Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 100. UAE Adoptive Cellular Immunotherapy Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 101. Methodology

Figure 102. Research Process and Data Source